result
coronaviru
diseas
pandem
urgent
worldwid
demand
treatment
due
factor
histori
prescript
infecti
diseas
avail
rel
low
cost
use
chloroquin
cq
hydroxychloroquin
hcq
test
vivo
vitro
abil
inhibit
caus
viru
sever
acut
respiratori
syndrom
coronaviru
howev
even
though
investig
note
therapeut
potenti
drug
import
consid
toxicolog
risk
necessari
care
ration
use
cq
hcq
studi
provid
inform
main
toxicolog
epidemiolog
aspect
consid
prophylaxi
treatment
use
cq
mainli
hcq
less
toxic
deriv
cq
shown
produc
better
result
inhibit
prolifer
base
upon
preliminari
test
coronaviru
diseas
pandem
produc
signific
impact
public
health
global
economi
due
hospit
death
high
complex
clinic
care
long
quarantin
period
requir
control
spread
caus
viru
sever
acut
respiratori
syndrom
coronaviru
scenario
high
infect
rate
occurr
sever
case
may
result
death
demand
effect
drug
treat
control
pandem
given
top
prioriti
health
polit
author
among
drug
current
test
vitro
vivo
remdesivir
ribavirin
chloroquin
cq
hydroxychloroquin
hcq
shown
promis
clinic
result
inhibit
viral
replic
zhang
et
al
howev
molecular
mechan
underli
therapeut
action
clinic
benefit
remain
still
explor
search
inform
regard
cq
hcq
toxic
prioriti
sinc
directli
contribut
design
random
clinic
trial
cabral
et
al
jorg
et
al
liu
et
al
stokkerman
trichona
yam
kwok
zhang
et
al
although
research
concern
use
cq
hcq
control
still
preliminari
potenti
use
drug
support
factor
includ
avail
low
cost
histori
use
treatment
rheumat
infecti
diseas
malaria
amebiasi
stokkerman
trichona
addit
grow
trend
prefer
hcq
less
toxic
deriv
cq
found
yield
better
result
inhibit
prolifer
liu
et
al
respect
advers
effect
recognit
hcq
produc
toxic
retina
tissu
may
consequ
result
irrevers
retinopathi
marmor
et
al
especi
case
prolong
exposur
drug
wolf
marmor
less
recurr
case
usual
prolong
exposur
hcq
cardiotox
toxicolog
effect
report
central
nervou
system
neuromyopathi
symptom
skelet
muscl
weak
gastrointestin
chang
stein
bell
ang
although
evid
damag
genet
materi
liver
cell
vitro
produc
antimalari
drug
guo
et
al
appar
studi
avail
address
genotox
drug
point
low
potenti
dna
damag
cq
test
perform
vitro
riccio
et
al
consid
urgenc
conduct
clinic
research
result
safe
effect
protocol
therapeut
use
cq
hcq
time
review
aim
present
discuss
relev
aspect
prevent
toxicolog
effect
treatment
gener
aspect
consid
prophylaxi
treatment
use
cq
hcq
summar
figur
figur
emphas
physicochem
properti
chloroquin
cq
hydroxychloroquin
hcq
cq
hcq
synthet
antimalari
develop
bark
cinchona
rubiacea
solubl
water
hcq
solubl
possess
hydroxyl
group
rapidli
fast
absorb
long
plasma
elimin
halflif
hr
respect
kalia
dutz
lead
tissu
bioaccumul
chronic
treatment
stokkerman
trichona
cytochrom
complex
respons
metabol
cq
hcq
liver
approxim
metabolit
excret
without
modif
kidney
kalia
dutz
cq
hcq
may
also
transport
across
placenta
drug
detect
breast
milk
rainsford
et
al
success
replic
virus
need
host
intracellular
medium
stabl
acid
ph
endosom
lysosom
golgi
complex
antivir
properti
cq
hcq
attribut
accumul
aminoquinolin
rais
ph
medium
lysosom
intracellular
acid
compart
organel
planton
koudriavtseva
import
emphas
treatment
consist
inhibit
viral
replic
also
control
inflammatori
process
reduc
product
proinflammatori
cytokin
mediat
albari
alim
regard
side
effect
main
toxicolog
outcom
initi
cq
hcq
report
medicalscientif
literatur
relat
retinopathi
neuromyopathi
cardiomyopathi
retin
pigment
epithelium
cq
hcq
affin
melanin
molecul
produc
effect
macular
cone
outsid
fovea
specif
retin
pigment
cell
react
accumul
extern
segment
photoreceptor
trigger
cq
hcq
result
decreas
phagocyt
activ
lysosom
extern
segment
photoreceptor
migrat
central
peripher
region
tissu
induc
epitheli
atrophi
irrevers
chang
photoreceptor
yam
kwok
mention
previous
due
long
plasma
elimin
halflif
cq
hcq
drug
slowli
excret
thu
even
treatment
stop
necessari
monitor
side
effect
sinc
pruritu
corneal
deposit
keratopathi
continu
maculopathi
retina
may
delay
occurr
regard
occurr
cardiomyopathi
neuromyopathi
metabol
mechan
underli
histolog
damag
mediat
hcq
similar
basic
compound
intracellular
medium
muscl
tissu
hcq
enter
lysosom
diffus
sinc
organel
acid
ph
within
lysosom
hcq
proton
accumul
inhibit
action
lysosom
phospholipas
result
vacuol
cardiac
skelet
muscl
cell
yogasundaram
et
al
liu
et
al
perform
metaanalysi
investig
effect
use
cq
hcq
pool
patient
rheumat
diseas
effect
cardiomyopathi
neuromyopathi
confirm
chatr
et
al
examin
cardiac
complic
attribut
cq
hcq
systemat
review
literatur
note
cqor
hcqrelat
cardiac
disord
rare
sever
advers
event
occur
longterm
administr
control
clinic
studi
still
lack
epidemiolog
clarifi
incid
cardiomyopathi
neuromyopathi
toxic
produc
retin
cell
comprehens
explor
mell
marmor
shown
figur
b
incid
cq
hcq
retin
toxic
increas
chronic
treatment
reinforc
hypothesi
bioaccumul
consid
daili
dose
cq
hcq
prescrib
vari
around
mg
year
treatment
patient
receiv
kg
drug
although
investig
found
incid
retinopathi
lower
mavrikaki
figur
studi
import
predictor
hydroxychloroquin
retin
toxic
durat
use
cumul
dose
et
al
two
aspect
need
consid
use
cq
hcq
treat
pandem
therefor
million
peopl
receiv
treatment
dose
use
acut
approach
viral
infect
often
much
higher
compar
util
cq
hcq
treatment
chronic
rheumat
diseas
touret
de
lamballeri
addit
anoth
import
epidemiolog
consider
fact
retinopathi
common
asian
patient
mell
marmor
analysi
result
obtain
research
investig
risk
toxic
associ
use
cq
hcq
et
al
gossec
et
al
evid
care
need
consid
prescrib
cq
andor
hcq
treatment
side
effect
prevent
reduc
figur
c
thu
main
challeng
consid
mani
epidemiolog
clinic
aspect
possibl
start
treatment
sens
import
know
histori
previou
ongo
use
cq
hcq
patient
infect
malaria
amebiasi
individu
chronic
diseas
rheumatoid
arthriti
system
lupu
also
relev
rememb
asian
patient
higher
risk
develop
retinopathi
patient
without
vision
problem
cardiovascular
diseas
need
period
monitor
treatment
cq
hcq
possibl
perform
simpl
test
measur
central
peripher
visual
acuiti
addit
symptom
ocular
pruritu
earli
sign
cardiac
arrhythmia
need
identifi
possibl
drug
interact
scientif
literatur
describ
kaolin
clay
antacid
interact
cq
hcq
may
reduc
antivir
antiinflammatori
activ
hand
cq
hcq
diminish
activ
antibiot
immunosuppress
ampicillin
cyclosporin
patient
treat
mefloquin
increas
risk
convuls
current
recommend
emphas
fact
toxic
relat
dose
calcul
real
weight
henc
prescript
daili
dose
cq
hcq
need
suitabl
patient
high
risk
present
advers
effect
consid
cumul
dose
mgkg
bodi
weightday
consid
high
risk
marmor
et
al
evid
use
cq
hcq
prevent
effect
effect
thu
clear
inform
regard
riskbenefit
ratio
cq
hcq
prescript
need
share
among
health
profession
extend
patient
popul
research
around
world
look
develop
targetspecif
drug
viru
current
approach
need
ground
practic
patient
care
minim
risk
rigor
screen
measur
dose
